MDT · 10-Q · 2026Q3 · Full report
Cardiac Device Demand
Medtronic plc · 2026-09-03 · Importance 46 · Surprise 56 · In source text
Electrophysiology Therapies sales increased 30%, driven by growth in the pulsed field ablation portfolio and higher demand for Cardiac Pacing Therapies and Defibrillation Solutions. The company expects continued adoption of Aurora EV-ICD, the Cobalt and Crome ICD and CRT-D portfolio, Micra transcatheter pacing, Azure pacing, SelectSecure 3830 leads, Reveal LINQ, and LINQ II. The TYRX Envelope, OmniaSecure defibrillation lead, and Affera mapping and ablation system with Sphere-9 catheter are also identified as growth products. These trends indicate continued procedure demand and portfolio expansion in cardiac rhythm management and ablation.
Key facts
- OmniaSecure defibrillation lead received CE Mark in March 2026. source
- Electrophysiology Therapies net sales for the three months ended July 31, 2026 increased 30 percent compared to the corresponding period in the prior fiscal year. source
Impact estimates
| metric | direction | stage | expected | basis |
|---|---|---|---|---|
| revenue | positive | probable | — | OmniaSecure defibrillation lead received CE Mark in March 2026. |
| revenue | positive | realized | — | Electrophysiology Therapies net sales for the three months ended July 31, 2026 increased 30 percent compared to the corresponding period… |